Mirtazapine
| Clinical data | |
|---|---|
| Trade names | Remeron, others |
| Other names | Mepirzapine; 6-Azamianserin; ORG-3770[1][2] |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a697009 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth, topical |
| Drug class | Noradrenergic and specific serotonergic antidepressant (NaSSA) |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 50%[7][5][8][9] |
| Protein binding | 85%[7][5][8][9] |
| Metabolism | Liver (CYP1A2, CYP2D6, CYP3A4)[7][5][8][9][10] |
| Metabolites | Desmethylmirtazapine (contributes 3–10% of activity)[10][7] |
| Elimination half-life | 20–40 hours[7][5][8][9] |
| Excretion | Urine: 75%[7] Feces: 15%[7][5][8][9] |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.080.027 |
| Chemical and physical data | |
| Formula | C17H19N3 |
| Molar mass | 265.360 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| Density | 1.22 g/cm3 |
| Melting point | 114 to 116 °C (237 to 241 °F) |
| Boiling point | 432 °C (810 °F) |
| Solubility in water | Soluble in methanol and chloroform mg/mL (20 °C) |
SMILES
| |
| |
| (verify) | |
Mirtazapine, sold under the brand name Remeron among others, is an atypical tetracyclic antidepressant, and as such is used primarily to treat depression.[10][11] Its effects may take up to four weeks but can also manifest as early as one to two weeks.[11][12] It is often used in cases of depression complicated by anxiety or insomnia.[10][13] The effectiveness of mirtazapine is comparable to other commonly prescribed antidepressants.[14] It is taken by mouth.[11]
Common side effects include sleepiness, dizziness, increased appetite, and weight gain.[11] Serious side effects may include mania, low white blood cell count, and increased suicide among children.[11] Withdrawal symptoms may occur with stopping.[15] It is not recommended together with a monoamine oxidase inhibitor,[11] although evidence supporting the danger of this combination has been challenged.[16] It is unclear if use during pregnancy is safe.[11] How it works is not clear, but it may involve blocking certain adrenergic and serotonin receptors.[10][11] Chemically, it is a tetracyclic antidepressant,[11] and is closely related to mianserin. It also has strong antihistaminergic effects.[10][11]
Mirtazapine came into medical use in the United States in 1996.[11] The patent expired in 2004, and generic versions are available.[11][17] In 2023, it was the 99th most commonly prescribed medication in the United States, with more than 6 million prescriptions.[18][19]
- ^ Cite error: The named reference
IndexNominum2000was invoked but never defined (see the help page). - ^ Cite error: The named reference
Drugs.comwas invoked but never defined (see the help page). - ^ "Mirtazapine Use During Pregnancy". Drugs.com. 23 September 2019. Archived from the original on 22 August 2020. Retrieved 4 March 2020.
- ^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
- ^ a b c d e f "Remeron- mirtazapine tablet, film coated; Remeronsoltab- mirtazapine tablet, orally disintegrating". DailyMed. 4 March 2024. Retrieved 1 September 2024.
- ^ "Mirataz- mirtazapine ointment". DailyMed. 5 April 2024. Retrieved 1 September 2024.
- ^ a b c d e f g Timmer CJ, Sitsen JM, Delbressine LP (June 2000). "Clinical pharmacokinetics of mirtazapine". Clinical Pharmacokinetics. 38 (6): 461–474. doi:10.2165/00003088-200038060-00001. PMID 10885584. S2CID 27697181.
- ^ a b c d e Cite error: The named reference
AXITwas invoked but never defined (see the help page). - ^ a b c d e Cite error: The named reference
EMCwas invoked but never defined (see the help page). - ^ a b c d e f Anttila SA, Leinonen EV (2001). "A review of the pharmacological and clinical profile of mirtazapine". CNS Drug Reviews. 7 (3): 249–264. doi:10.1111/j.1527-3458.2001.tb00198.x. PMC 6494141. PMID 11607047.
- ^ a b c d e f g h i j k l "Mirtazapine Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 10 January 2021. Retrieved 20 November 2018.
- ^ Cite error: The named reference
Cochrane2011was invoked but never defined (see the help page). - ^ Nutt DJ (June 2002). "Tolerability and safety aspects of mirtazapine". Human Psychopharmacology. 17 (Suppl 1): S37 – S41. doi:10.1002/hup.388. PMID 12404669. S2CID 23699759.
- ^ "[129] Mirtazapine: Update on efficacy, safety, dose response". www.ti.ubc.ca. Archived from the original on 7 May 2021. Retrieved 8 May 2021.
- ^ British national formulary: BNF 74 (74 ed.). British Medical Association. 2017. p. 354. ISBN 978-0857112989.
- ^ Cite error: The named reference
pmid16342227was invoked but never defined (see the help page). - ^ Schatzberg AF, Cole JO, DeBattista C (2010). "3". Manual of Clinical Psychopharmacology (7th ed.). Arlington, VA: American Psychiatric Publishing. ISBN 978-1-58562-377-8.
- ^ "Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
- ^ "Mirtazapine Drug Usage Statistics, United States, 2013 - 2023". ClinCalc. Retrieved 18 August 2025.